Page 7 - Van Rompay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion. Hyloris’ partner AFT Pharmaceuticals works together with distribution partners with strong local presence to commercialise the product...

Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV, a Novel Non-Opioid Pain Treatment, in Key European Markets Liège, Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion...

Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that its partner for Maxigesic IV, AFT Pharmaceuticals (“AFT”), has extended its existing license and distribution agreement with Pharma Bavaria International for the commercialisation of Maxigesic IV, a novel, patented, non-opioid treatment for post-operative pain, in South America. The extended collaboration further builds on the agreement signed with Pharma Bavaria in February 2020 for ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV Hyloris Pharmaceuticals SAApril 28, 2021 GMT Hikma Pharmaceuticals, a leading supplier of complex, injectable hospital products in the U.S., to commercialise Maxigesic IV in the U.S. Hyloris is eligible to receive $4 million in regulatory based milestones as well as commercial milestones and a share of net profit Maxigesic IV has potential to combat the opioid epidemic in pain management Liège, Belgium – 28 April 2021 �...

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results On track to fuel the pipeline with =4 new product candidates in 2021 Strong cash position of €64 million year-end to execute ambitious growth plan 14 commercial products expected by 2024 Conference call and Liège, Belgium - 9 March 2021 - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 De...